8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Mar 3, 2026·SEC
Haemonetics Corporation(HAE)Earnings, Financials & Key Ratios
HAE•NYSE
36.2× P/E·Price updated Jun 19, 2026
AboutHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Show more
- Revenue$1.33B-2.0%
- EBITDA$397M+20.1%
- Net Income$97M-42.0%
- EPS (Diluted)2.05-38.1%
- Gross Margin55.74%-2.6%
- EBITDA Margin29.77%+22.5%
- Operating Margin18.1%+11.0%
- Net Margin7.29%-40.8%
- ROE12.03%-36.1%
HAE Key Insights
Haemonetics Corporation (HAE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 19.5% free cash flow margin
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 6.7% through buybacks
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when HAE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HAE Price & Volume
Haemonetics Corporation (HAE) stock price & volume — 10-year historical chart
Loading chart...
HAE Growth Metrics
Haemonetics Corporation (HAE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.91%
5 Years8.91%
3 Years4.51%
TTM-1.97%
Profit CAGR
10 Years-
5 Years4.13%
3 Years-5.53%
TTM-41.97%
EPS CAGR
10 Years-
5 Years5.75%
3 Years-2.91%
TTM-38.97%
Return on Capital
10 Years7.88%
5 Years9.72%
3 Years11.03%
Last Year12.11%
HAE Recent Earnings
Haemonetics Corporation (HAE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.29+0.8%
$1.28
Rev
$346M+2.8%
$337M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.31+3.1%
$1.27
Rev
$339M+2.1%
$332M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.27+13.4%
$1.12
Rev
$327M-0.7%
$330M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.10+8.9%
$1.01
Rev
$321M+0.4%
$320M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.29vs $1.28+0.8% | $346Mvs $337M+2.8% |
| Q1 2026 | Feb 5, 2026 | $1.31vs $1.27+3.1% | $339Mvs $332M+2.1% |
| Q4 2025 | Nov 6, 2025 | $1.27vs $1.12+13.4% | $327Mvs $330M-0.7% |
| Q3 2025 | Aug 7, 2025 | $1.10vs $1.01+8.9% | $321Mvs $320M+0.4% |
Based on last 12 quarters of dataView full earnings history →
HAE Peer Comparison
Haemonetics Corporation (HAE) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TFX | 5.62B | 127.00 | -6.27 | -34.61% | -35.89% | -28.27% | 0.87 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ITGR | 3.13B | 90.96 | 31.47 | 7.57% | 7.67% | 8.23% | 0.80 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 NNOX | 109.19M | 1.67 | -1.84 | 13.91% | -452.82% | -35.55% | 0.04 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 |
Compare HAE vs Peers
Haemonetics Corporation (HAE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HAE Income Statement
Haemonetics Corporation (HAE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 903.92M | 967.58M | 988.48M | 870.46M | 993.2M | 1.17B | 1.31B | 1.36B | 1.33B |
Revenue Growth % | 2.01% | 7.04% | 2.16% | -11.94% | 14.1% | 17.67% | 12.01% | 3.95% | -1.97% |
Cost of Goods Sold | 492.01M | 550.04M | 500.66M | 442.02M | 462.43M | 545.79M | 597.14M | 582.28M | 590.44M |
COGS % of Revenue | 54.43% | 56.85% | 50.65% | 50.78% | 46.56% | 46.7% | 45.62% | 42.79% | 44.26% |
Gross Profit | 411.91M▲ 0% | 417.54M▲ 1.4% | 487.82M▲ 16.8% | 428.45M▼ 12.2% | 530.77M▲ 23.9% | 622.87M▲ 17.4% | 711.91M▲ 14.3% | 778.55M▲ 9.4% | 743.59M▼ 4.5% |
Gross Margin % | 45.57% | 43.15% | 49.35% | 49.22% | 53.44% | 53.3% | 54.38% | 57.21% | 55.74% |
Gross Profit Growth % | 8.83% | 1.37% | 16.83% | -12.17% | 23.88% | 17.35% | 14.3% | 9.36% | -4.49% |
Operating Expenses | 355.75M | 333.99M | 384.47M | 338.7M | 450.02M | 466.84M | 547.03M | 556.73M | 502.19M |
OpEx % of Revenue | 39.36% | 34.52% | 38.9% | 38.91% | 45.31% | 39.95% | 41.79% | 40.91% | 37.64% |
Selling, General & Admin | 316.52M | 298.28M | 266.33M | 263.83M | 332.2M | 373.95M | 420.82M | 422.05M | 442.42M |
SG&A % of Revenue | 35.02% | 30.83% | 26.94% | 30.31% | 33.45% | 32% | 32.15% | 31.01% | 33.16% |
Research & Development | 39.23M | 35.71M | 39.08M | 40.66M | 55.2M | 58.63M | 63.03M | 69.42M | 59.77M |
R&D % of Revenue | 4.34% | 3.69% | 3.95% | 4.67% | 5.56% | 5.02% | 4.82% | 5.1% | 4.48% |
Other Operating Expenses | 0 | 0 | 79.05M | 34.21M | 62.62M | 34.26M | 63.18M | 65.26M | 0 |
Operating Income | 56.16M▲ 0% | 83.55M▲ 48.8% | 103.35M▲ 23.7% | 89.75M▼ 13.2% | 80.75M▼ 10.0% | 156.03M▲ 93.2% | 164.88M▲ 5.7% | 221.82M▲ 34.5% | 241.4M▲ 8.8% |
Operating Margin % | 6.21% | 8.63% | 10.46% | 10.31% | 8.13% | 13.35% | 12.6% | 16.3% | 18.1% |
Operating Income Growth % | 389.75% | 48.77% | 23.71% | -13.16% | -10.02% | 93.23% | 5.67% | 34.53% | 8.83% |
EBITDA | 145.4M | 192.96M | 195.54M | 174.03M | 167.3M | 240.84M | 253.5M | 330.7M | 397.12M |
EBITDA Margin % | 16.09% | 19.94% | 19.78% | 19.99% | 16.84% | 20.61% | 19.36% | 24.3% | 29.77% |
EBITDA Growth % | 124.9% | 32.71% | 1.34% | -11% | -3.87% | 43.96% | 5.26% | 30.46% | 20.08% |
D&A (Non-Cash Add-back) | 89.25M | 109.42M | 92.19M | 84.29M | 86.55M | 84.81M | 88.61M | 108.89M | 155.72M |
EBIT | 64.16M | 83.55M | 165.75M | 100.1M | 105.17M | 167.2M | 206.84M | 247.1M | 241.4M |
Net Interest Income | -4.53M | -9.91M | -16.2M | -16.83M | -17.12M | -14.63M | -13.02M | -9.75M | -28.7M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 4.53M | 9.91M | 16.2M | 16.83M | 17.12M | 14.63M | 13.02M | 9.75M | 28.7M |
Other Income/Expense | 3.48M | -9.91M | -16.2M | -16.83M | -17.12M | -14.63M | -13.02M | -9.75M | -113.37M |
Pretax Income | 59.63M▲ 0% | 73.63M▲ 23.5% | 87.15M▲ 18.4% | 72.91M▼ 16.3% | 63.63M▼ 12.7% | 141.4M▲ 122.2% | 151.87M▲ 7.4% | 212.07M▲ 39.6% | 128.03M▼ 39.6% |
Pretax Margin % | 6.6% | 7.61% | 8.82% | 8.38% | 6.41% | 12.1% | 11.6% | 15.58% | 9.6% |
Income Tax | 14.06M | 18.61M | 10.63M | -6.56M | 20.25M | 26M | 34.31M | 44.39M | 30.72M |
Effective Tax Rate % | 23.58% | 25.28% | 12.19% | -8.99% | 31.83% | 18.39% | 22.59% | 20.93% | 24% |
Net Income | 45.57M▲ 0% | 55.02M▲ 20.7% | 76.53M▲ 39.1% | 79.47M▲ 3.8% | 43.38M▼ 45.4% | 115.4M▲ 166.1% | 117.56M▲ 1.9% | 167.68M▲ 42.6% | 97.31M▼ 42.0% |
Net Margin % | 5.04% | 5.69% | 7.74% | 9.13% | 4.37% | 9.87% | 8.98% | 12.32% | 7.29% |
Net Income Growth % | 273.49% | 20.73% | 39.09% | 3.85% | -45.42% | 166.05% | 1.87% | 42.64% | -41.97% |
Net Income (Continuing) | 45.57M | 55.02M | 76.53M | 79.47M | 43.38M | 115.4M | 117.56M | 167.68M | 97.31M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.85▲ 0% | 1.04▲ 22.4% | 1.48▲ 42.3% | 1.55▲ 4.7% | 0.84▼ 45.8% | 2.24▲ 166.7% | 2.29▲ 2.2% | 3.31▲ 44.5% | 2.05▼ 38.1% |
EPS Growth % | 266.67% | 22.35% | 42.31% | 4.73% | -45.81% | 166.67% | 2.23% | 44.54% | -38.07% |
EPS (Basic) | 0.86 | 1.07 | 1.51 | 1.57 | 0.85 | 2.27 | 2.32 | 3.31 | 2.05 |
Diluted Shares Outstanding | 53.5M | 52.94M | 51.81M | 51.29M | 51.35M | 51.42M | 51.4M | 50.73M | 47.35M |
Basic Shares Outstanding | 52.76M | 51.53M | 50.69M | 50.69M | 51.05M | 50.78M | 50.71M | 50.33M | 47.18M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
HAE Balance Sheet
Haemonetics Corporation (HAE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 521.18M | 576.12M | 603.64M | 693.55M | 756.03M | 769.72M | 768.9M | 934.98M | 834.88M |
Cash & Short-Term Investments | 180.17M | 169.35M | 137.31M | 192.31M | 259.5M | 284.47M | 178.8M | 306.76M | 245.44M |
Cash Only | 180.17M | 169.35M | 137.31M | 192.31M | 259.5M | 284.47M | 178.8M | 306.76M | 245.44M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 151.23M | 185.03M | 165.21M | 127.56M | 159.38M | 179.14M | 206.56M | 202.66M | 216.85M |
Days Sales Outstanding | 61.06 | 69.8 | 61 | 53.49 | 58.57 | 55.95 | 57.6 | 54.36 | 59.33 |
Inventory | 160.8M | 194.34M | 270.28M | 322.61M | 293.03M | 259.38M | 317.2M | 365.14M | 306.37M |
Days Inventory Outstanding | 119.29 | 128.96 | 197.04 | 266.4 | 231.29 | 173.46 | 193.89 | 228.89 | 189.39 |
Other Current Assets | 28.98M | 27.41M | 0 | 0 | 0 | 46.73M | 66.34M | 60.41M | 66.21M |
Total Non-Current Assets | 716.16M | 698.65M | 663.47M | 1.13B | 1.1B | 1.17B | 1.43B | 1.52B | 1.56B |
Property, Plant & Equipment | 332.16M | 343.98M | 253.4M | 217.56M | 258.48M | 310.88M | 366.63M | 284.05M | 305.76M |
Fixed Asset Turnover | 2.72x | 2.81x | 3.90x | 4.00x | 3.84x | 3.76x | 3.57x | 4.79x | 4.36x |
Goodwill | 211.4M | 210.82M | 210.65M | 466.44M | 467.29M | 466.23M | 565.08M | 604.27M | 656.37M |
Intangible Assets | 156.59M | 127.69M | 133.11M | 365.48M | 310.26M | 275.77M | 406.12M | 455.74M | 447.65M |
Long-Term Investments | -3.96M | -4.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 16.02M | 16.16M | 62.38M | 70.88M | 63.2M | 106.97M | 81.12M | 164.11M | 151.26M |
Total Assets | 1.24B▲ 0% | 1.27B▲ 3.0% | 1.27B▼ 0.6% | 1.82B▲ 43.6% | 1.86B▲ 2.2% | 1.93B▲ 4.0% | 2.2B▲ 13.5% | 2.45B▲ 11.6% | 2.4B▼ 2.2% |
Asset Turnover | 0.73x | 0.76x | 0.78x | 0.48x | 0.53x | 0.60x | 0.60x | 0.56x | 0.56x |
Asset Growth % | -0.11% | 3.02% | -0.6% | 43.63% | 2.19% | 4.04% | 13.48% | 11.63% | -2.25% |
Total Current Liabilities | 384.7M | 235.76M | 274.82M | 253.5M | 442.27M | 251.82M | 300.38M | 578.11M | 282.6M |
Accounts Payable | 55.27M | 63.36M | 50.73M | 50.29M | 58.37M | 63.93M | 73.36M | 67M | 0 |
Days Payables Outstanding | 41 | 42.05 | 36.98 | 41.53 | 46.07 | 42.75 | 44.84 | 42 | - |
Short-Term Debt | 194.26M | 27.67M | 76.98M | 17.02M | 214.15M | 11.78M | 10.23M | 303.56M | 5.01M |
Deferred Revenue (Current) | 25.81M | 27.28M | 28.84M | 26.27M | 26.81M | 30.21M | 31.24M | 43.35M | 0 |
Other Current Liabilities | 34.51M | 55.8M | 44.92M | 80.95M | 87.2M | 81.42M | 104.85M | 104.78M | 277.58M |
Current Ratio | 1.35x | 2.44x | 2.20x | 2.74x | 1.71x | 3.06x | 2.56x | 1.62x | 2.95x |
Quick Ratio | 0.94x | 1.62x | 1.21x | 1.46x | 1.05x | 2.03x | 1.50x | 0.99x | 1.87x |
Cash Conversion Cycle | 139.35 | 156.71 | 221.06 | 278.36 | 243.79 | 186.66 | 206.64 | 241.25 | - |
Total Non-Current Liabilities | 100.21M | 371.14M | 405.18M | 834.76M | 668.04M | 865.01M | 935.25M | 1.05B | 1.32B |
Long-Term Debt | 59.42M | 322.45M | 305.51M | 690.59M | 559.44M | 754.1M | 797.56M | 921.23M | 1.22B |
Capital Lease Obligations | 0 | 0 | 52.01M | 62.96M | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 9.38M | 22.8M | 14M | 43.83M | 28.73M | 36.2M | 62.64M | 62.58M | 0 |
Other Non-Current Liabilities | 34.26M | 25.89M | 33.65M | 37.38M | 79.88M | 74.72M | 75.04M | 68.19M | 97.44M |
Total Liabilities | 484.91M | 606.9M | 680M | 1.09B | 1.11B | 1.12B | 1.24B | 1.63B | 1.6B |
Total Debt | 253.68M | 350.12M | 441.81M | 778.28M | 780.78M | 765.89M | 807.79M | 1.22B | 1.22B |
Net Debt | 73.51M | 180.77M | 304.5M | 585.97M | 521.29M | 481.42M | 628.99M | 918.02M | 979.14M |
Debt / Equity | 0.34x | 0.52x | 0.75x | 1.06x | 1.04x | 0.94x | 0.84x | 1.49x | 1.54x |
Debt / EBITDA | 1.74x | 1.81x | 2.26x | 4.47x | 4.67x | 3.18x | 3.19x | 3.70x | 3.08x |
Net Debt / EBITDA | 0.51x | 0.94x | 1.56x | 3.37x | 3.12x | 2.00x | 2.48x | 2.78x | 2.47x |
Interest Coverage | 14.18x | 8.43x | 10.23x | 5.95x | 6.14x | 11.43x | 15.89x | 25.35x | 8.41x |
Total Equity | 752.43M▲ 0% | 667.87M▼ 11.2% | 587.11M▼ 12.1% | 731.67M▲ 24.6% | 749.42M▲ 2.4% | 818M▲ 9.2% | 959.96M▲ 17.4% | 820.84M▼ 14.5% | 796.32M▼ 3.0% |
Equity Growth % | 1.73% | -11.24% | -12.09% | 24.62% | 2.43% | 9.15% | 17.35% | -14.49% | -2.99% |
Book Value per Share | 14.06 | 12.62 | 11.33 | 14.26 | 14.59 | 15.91 | 18.68 | 16.18 | 16.82 |
Total Shareholders' Equity | 752.43M | 667.87M | 587.11M | 731.67M | 749.42M | 818M | 959.96M | 820.84M | 796.32M |
Common Stock | 523K | 510K | 503K | 509K | 511K | 504K | 508K | 482K | 0 |
Retained Earnings | 266.94M | 161.42M | 78.51M | 157.98M | 202.39M | 253.17M | 360.46M | 352.17M | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -18.99M | -30.38M | -45.13M | -29.55M | -25.95M | -30.38M | -35.63M | -55.08M | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HAE Cash Flow Statement
Haemonetics Corporation (HAE) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 220.35M | 159.28M | 158.22M | 108.81M | 172.26M | 273.06M | 181.75M | 181.72M | 293.22M |
Operating CF Margin % | 24.38% | 16.46% | 16.01% | 12.5% | 17.34% | 23.37% | 13.88% | 13.35% | 21.98% |
Operating CF Growth % | 37.94% | -27.71% | -0.67% | -31.23% | 58.32% | 58.51% | -33.44% | -0.01% | 61.35% |
Net Income | 45.57M | 55.02M | 76.53M | 79.47M | 43.38M | 115.4M | 117.56M | 167.68M | 97.31M |
Depreciation & Amortization | 89.25M | 109.42M | 110.29M | 84.29M | 97.75M | 93.31M | 97.22M | 115.59M | 155.72M |
Stock-Based Compensation | 13.03M | 17.19M | 20.45M | 25.52M | 24.36M | 25.58M | 28.33M | 29.64M | 0 |
Deferred Taxes | -5.83M | 13.35M | -6.96M | -19.87M | 5.01M | 4.78M | -11.04M | -5.22M | -26.47M |
Other Non-Cash Items | 1.85M | 27.05M | 42.47M | -919K | 16.95M | 8.48M | 24.39M | -24M | 90.32M |
Working Capital Changes | 76.49M | -62.75M | -84.56M | -59.68M | -15.18M | 25.5M | -74.7M | -101.96M | -23.65M |
Change in Receivables | 5.09M | -38.06M | 18.86M | 44.12M | -34.97M | -24.42M | -24.19M | 6.96M | -14.88M |
Change in Inventory | 14.38M | -39.32M | -84.72M | -38.91M | 24.31M | 30.75M | -60.06M | -64.7M | 47.36M |
Change in Payables | 41.4M | 17.74M | -17.31M | 0 | 0 | 39.82M | 44.58M | 0 | -16.57M |
Cash from Investing | -63.04M | -116.15M | -57.18M | -425.44M | -86.34M | -143.79M | -322.39M | -161.9M | -179.55M |
Capital Expenditures | -74.8M | -118.96M | -48.76M | -37.04M | -96.51M | -110.19M | -66.3M | -39.28M | -92.96M |
CapEx % of Revenue | 8.27% | 12.29% | 4.93% | 4.26% | 9.72% | 9.43% | 5.06% | 2.89% | 6.97% |
Acquisitions | 9M | 2.81M | -25.19M | -390.22M | 8.14M | -2M | -240.54M | -107.61M | 1.38M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 2.76M | 2.81M | 16.77M | 1.81M | 2.02M | 1.61M | 0 | -15M | -87.96M |
Cash from Financing | -120.64M | -50.63M | -131.21M | 367.45M | -15.75M | -100.36M | 38.16M | 108.82M | -178.46M |
Debt Issued (Net) | -60.98M | 95.93M | 31.88M | 418.13M | -17.5M | -9.63M | 37.75M | 447.31M | -6.25M |
Equity Issued (Net) | -100M | -160M | -175M | 0 | 0 | -75M | 7.21M | -225M | -167.11M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -100M | -160M | -175M | 0 | 0 | -75M | 0 | -225M | -175M |
Other Financing | 40.34M | 13.45M | 11.92M | -50.67M | 1.75M | -15.74M | -6.81M | -113.49M | -5.1M |
Net Change in Cash | 40.6M▲ 0% | -10.82M▼ 126.6% | -32.04M▼ 196.2% | 54.99M▲ 271.6% | 67.19M▲ 22.2% | 24.97M▼ 62.8% | -105.67M▼ 523.2% | 127.96M▲ 221.1% | -61.32M▼ 147.9% |
Free Cash Flow | 145.55M▲ 0% | 40.32M▼ 72.3% | 109.46M▲ 171.5% | 71.77M▼ 34.4% | 75.75M▲ 5.6% | 162.87M▲ 115.0% | 115.45M▼ 29.1% | 142.45M▲ 23.4% | 260.44M▲ 82.8% |
FCF Margin % | 16.1% | 4.17% | 11.07% | 8.24% | 7.63% | 13.94% | 8.82% | 10.47% | 19.52% |
FCF Growth % | 74.1% | -72.3% | 171.48% | -34.44% | 5.56% | 114.99% | -29.11% | 23.38% | 82.83% |
FCF per Share | 2.72 | 0.76 | 2.11 | 1.40 | 1.48 | 3.17 | 2.25 | 2.81 | 5.50 |
FCF Conversion (FCF/Net Income) | 4.84x | 2.90x | 2.07x | 1.37x | 3.97x | 2.37x | 1.55x | 1.08x | 3.01x |
Interest Paid | 7.66M | 13.12M | 12.54M | 7.82M | 6.19M | 13.59M | 0 | 16.53M | 0 |
Taxes Paid | 9.08M | 8.21M | 11.51M | 12.49M | 24.3M | 17.97M | 0 | 49.29M | 0 |
HAE Key Ratios
Haemonetics Corporation (HAE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -3.6% | 6.11% | 7.75% | 12.2% | 12.05% | 5.86% | 14.72% | 13.22% | 18.83% | 12.03% |
Return on Invested Capital (ROIC) | -1.51% | 4.84% | 7.48% | 8.91% | 6.09% | 4.68% | 9.11% | 8.56% | 10% | 10.3% |
Gross Margin | 42.71% | 45.57% | 43.15% | 49.35% | 49.22% | 53.44% | 53.3% | 54.38% | 57.21% | 55.74% |
Net Margin | -2.96% | 5.04% | 5.69% | 7.74% | 9.13% | 4.37% | 9.87% | 8.98% | 12.32% | 7.29% |
Debt / Equity | 0.43x | 0.34x | 0.52x | 0.75x | 1.06x | 1.04x | 0.94x | 0.84x | 1.49x | 1.54x |
Interest Coverage | 4.84x | 14.18x | 8.43x | 10.23x | 5.95x | 6.14x | 11.43x | 15.89x | 25.35x | 8.41x |
FCF Conversion | -6.08x | 4.84x | 2.90x | 2.07x | 1.37x | 3.97x | 2.37x | 1.55x | 1.08x | 3.01x |
Revenue Growth | -2.5% | 2.01% | 7.04% | 2.16% | -11.94% | 14.1% | 17.67% | 12.01% | 3.95% | -1.97% |
Related:HAE Dividend History·HAE Revenue History·HAE Price History·HAE P/E History·HAE Financial Ratios·HAE Institutional Holders
HAE SEC Filings & Documents
Haemonetics Corporation (HAE) SEC filings — annual & quarterly reports (10-K, 10-Q)
HAE Frequently Asked Questions
Haemonetics Corporation (HAE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Haemonetics Corporation (HAE) reported $1.33B in revenue for fiscal year 2026. This represents a 331% increase from $309.8M in 1997.
Haemonetics Corporation (HAE) saw revenue decline by 2.0% over the past year.
Yes, Haemonetics Corporation (HAE) is profitable, generating $97.3M in net income for fiscal year 2026 (7.3% net margin).
Dividend & Returns
Haemonetics Corporation (HAE) has a return on equity (ROE) of 12.0%. This is reasonable for most industries.
Haemonetics Corporation (HAE) generated $260.4M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.